Cargando…

A phase 1 study to evaluate the safety, tolerability and pharmacokinetics of TAK‐041 in healthy participants and patients with stable schizophrenia

AIMS: TAK‐041 (NBI‐1065846), an orally available, investigational, small molecule agonist of GPR139, an orphan G‐protein‐coupled receptor, has shown promise in preclinical studies for the treatment of symptoms associated with schizophrenia. Here, we report the results from a phase 1 study to evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yin, Wei, Han, David, Khudyakov, Polyna, Behrje, Rhett, Posener, Joel, Laurenza, Antonio, Arkilo, Dimitrios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544063/ https://www.ncbi.nlm.nih.gov/pubmed/35277995 http://dx.doi.org/10.1111/bcp.15305

Ejemplares similares

Safety, pharmacokinetics and pharmacodynamics of TAK‐418, a novel inhibitor of the epigenetic modulator lysine‐specific demethylase 1A
por: Yin, Wei, et al.
Publicado: (2021)

Evaluation of the pharmacokinetics of trazpiroben (TAK‐906) in the presence and absence of the proton pump inhibitor esomeprazole
por: Kaur Mukker, Jatinder, et al.
Publicado: (2022)

Safety, pharmacokinetics and quantitative EEG modulation of TAK‐071, a novel muscarinic M1 receptor positive allosteric modulator, in healthy subjects
por: Yin, Wei, et al.
Publicado: (2021)

Pharmacokinetic Interaction Between Fingolimod and Carbamazepine in Healthy Subjects
por: David, Olivier J., et al.
Publicado: (2018)

S180. THE SELECTIVE GPR139 AGONIST TAK-041 REVERSES ANHEDONIA AND SOCIAL INTERACTION DEFICITS IN RODENT MODELS RELATED TO NEGATIVE SYMPTOMS IN SCHIZOPHRENIA
por: Schiffer, Hans, et al.
Publicado: (2020)

Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti‐CD38 cytolytic antibody TAK‐079 in healthy subjects
por: Fedyk, Eric R., et al.
Publicado: (2020)

Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants
por: Humeniuk, Rita, et al.
Publicado: (2023)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects
por: Sakurai, Yuuichi, et al.
Publicado: (2015)

Endogenous dopamine release in the human brain as a pharmacodynamic biomarker: evaluation of the new GPR139 agonist TAK-041 with [(11)C]PHNO PET
por: Rabiner, Eugenii A., et al.
Publicado: (2021)

Pharmacokinetic, Safety, and Tolerability Evaluations of Gepotidacin (GSK2140944) in Healthy Japanese Participants
por: Barth, Aline, et al.
Publicado: (2022)

No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Buprenorphine/Naloxone in Healthy Participants and Participants Receiving Stable Opioid Agonist Therapy
por: Feng, Hwa‐Ping, et al.
Publicado: (2018)

B Physics in ATLAS (ATL-PHYS-94-041)
por: Eerola, Paule Anna Mari, et al.
Publicado: (1994)

AB041. Evolution of PDE5 inhibitors in Korea
por: Moon, Du Geon
Publicado: (2015)

SUN-041 Estrogen Pharmacogenetics in Patients with Turner Syndrome
por: Scalco, Renata, et al.
Publicado: (2019)

MON-LB041 Pheochromocytoma - Illusive Myriad of Symptoms
por: Gunda, Mouna, et al.
Publicado: (2020)

A Pharmacokinetic, Safety, and Tolerability Trial of Palovarotene in Healthy Japanese and Non-Japanese Participants
por: Dube, Louise, et al.
Publicado: (2023)

A Randomized Multiple Dose Pharmacokinetic Study of a Novel PDE10A Inhibitor TAK-063 in Subjects with Stable Schizophrenia and Japanese Subjects and Modeling of Exposure Relationships to Adverse Events
por: Goldsmith, Paul, et al.
Publicado: (2017)

Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects
por: Jenkins, H, et al.
Publicado: (2015)

The Effect of Hepatic Impairment on the Pharmacokinetics of Intravenously Administered Felcisetrag (TAK‐954)
por: Czerniak, Richard, et al.
Publicado: (2022)

Safety, tolerability, and pharmacokinetics of a single ascending subcutaneous dose of GSK3772847 in healthy participants
por: Pefani, Eleni, et al.
Publicado: (2023)

Effects of Itraconazole and Rifampin on the Pharmacokinetics of Mobocertinib (TAK‐788), an Oral Epidermal Growth Factor Receptor Inhibitor, in Healthy Volunteers
por: Zhang, Steven, et al.
Publicado: (2021)

Active or Passive Exposure to Tobacco Smoking and Allergic Rhinitis, Allergic Dermatitis, and Food Allergy in Adults and Children: A Systematic Review and Meta-Analysis
por: Saulyte, Jurgita, et al.
Publicado: (2014)

P01-041 – Patient management and rare FMF symptoms
por: Moradian, MM, et al.
Publicado: (2013)

PW02-041 - Canakinumab treatment regimens in CAPS-patients
por: Hofer, F, et al.
Publicado: (2013)

AB041. Perioperative nursing care of penile pacemaker implantation
por: Han, Di
Publicado: (2017)

P041 The Impact of Simulated Night Shifts on Executive Functioning
por: Greer, E, et al.
Publicado: (2021)

A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor
por: Tsai, Max, et al.
Publicado: (2016)

Dietary interventions to prevent and manage diabetes in worksite settings: a meta-analysis
por: Shrestha, Archana, et al.
Publicado: (2017)

Assessment of pharmacokinetics, safety, and tolerability following twice‐daily administration of molnupiravir for 10 days in healthy participants
por: Iwamoto, Marian, et al.
Publicado: (2023)

A041 DETECTION OF SARS-COV-2 ANTIBODIES IN IMMUNOGLOBULIN PRODUCTS
por: Cousins, K., et al.
Publicado: (2021)

ODP041 Hearing Loss Reveals Dopamine-secreting Metastatic Paraganglioma
por: Cutrone, Lauren S, et al.
Publicado: (2022)

Single‐Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAK‐788) in Healthy Volunteers: Low‐Fat Meal Effect and Relative Bioavailability of 2 Capsule Products
por: Zhang, Steven, et al.
Publicado: (2021)

Pharmacokinetic Interactions and Tolerability of Rosuvastatin and Ezetimibe: A Randomized, Phase 1, Crossover Study in Healthy Chinese Participants
por: Wang, Lu, et al.
Publicado: (2022)

Safety, Tolerability, and Pharmacokinetics of Benralizumab: A Phase 1, Randomized, Single-Blind Study of Healthy Chinese Participants
por: Cheung, Tommy Tsang, et al.
Publicado: (2023)

Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants
por: Perera, Vidya, et al.
Publicado: (2022)

AB041. Experience in the use of collagenase clostridium histolyticum in the management of Peyronie’s disease
por: Jad, Amr, et al.
Publicado: (2016)

Elucidating the Antimycobacterial Mechanism of Action of Decoquinate Derivative RMB041 Using Metabolomics
por: Knoll, Kirsten E., et al.
Publicado: (2021)

O041 Exploring the Landscape of Sleep Data Resources: A Literature Survey
por: Chen, L, et al.
Publicado: (2023)

Preclinical characterization of AMPA receptor potentiator TAK‐137 as a therapeutic drug for schizophrenia
por: Tanaka, Maiko, et al.
Publicado: (2019)

Safety, tolerability and pharmacokinetics of GSK3008348, a novel integrin αvβ6 inhibitor, in healthy participants
por: Maden, Charlotte H., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_g5keorb85sranef47kdajsfh4a